Celgene (CELG)/Juno Therapeutics (JUNO) Deal a 'Win-Win', Leerink Partners Says

Leerink Partners analyst Howard Liang views Celgene's (NASDAQ: CELG) deal with Juno Therapeutics (NASDAQ: JUNO) as a "win-win."

Liang commented, "We believe this deal is mutually beneficial to each party, with JUNO receiving very substantial upfront funding, recognition from an industry leader with heritage in cellular therapy while maintaining rights in North America and CELG leaping to the forefront of cell-based immunotherapy and gaining access to potential CAR-T and TCR therapies. With additional future business development and profit-sharing opportunities allowed as part of the collaboration, this deal should position both companies as leaders in the adoptive T-cell therapy space."

The firm maintained an Outperform rating and price target of $150 on CELG and an Outperform rating and price target of $74 on JUNO.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $114.91 yesterday.

You May Also Be Interested In

• Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
• VistaGen Therapeutics (VTGN) Reports Positive Results from Phase 2A Pilot Study of PH15
• Premier Financial Corp. (PFC) PT Raised to $22 at Piper Sandler